Prevalence and risk factors of SARS-CoV-2 antibody responses among healthcare workers (June 2020-November 2021).

Autor:	Barrufet MP; Infectious Disease Unit, Department of Internal Medicine, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain., Serra-Prat M; Research Unit, Fundació Salut del Consorci Sanitari del Maresme, Mataró, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain., Palomera E; Research Unit, Fundació Salut del Consorci Sanitari del Maresme, Mataró, Barcelona, Spain., Ruiz A; Laboratori de Referència de Catalunya, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain., Tapias G; Occupational Health Unit, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain., Montserrat N; Occupational Health Unit, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain., Valladares N; Occupational Health Unit, Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain., Ruz FJ; Information Technology Department, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain., Bolívar-Prados M; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.; Drug Research Ethics Committee (CEIm), Consorci Sanitari del Maresme, Mataró, Barcelona, Spain., Clavé P; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.; Research and Academic Department, Hospital de Mataró, Mataró, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	European journal of public health [Eur J Public Health] 2023 Oct 10; Vol. 33 (5), pp. 923-929.
DOI:	10.1093/eurpub/ckad093
Abstrakt:	Background: To assess SARS-CoV-2 seroprevalence in healthcare workers (HCW) with sampling in June and October 2020 and April and November 2021. Methods: Observational and prospective study in 2455 HCW with serum sampling. Antibodies against SARS-CoV-2 nucleocapsid and occupational, social and health risk factors were assessed at each time point. Results: Seropositivity for SARS-CoV-2 in HCW increased from 11.8% in June 2020 to 28.4% in November 2021. Of those with a positive test in June 2020, 92.1% remained with a positive test, 6.7% had an indeterminate test and 1.1% had a negative test in November 2021. Non-diagnosed carriers represented 28.6% in June 2020 and 14.6% in November 2021. Nurses and nursing assistants showed the highest prevalence of seropositivity. Close contact (at home or in the hospital) with Covid-19 cases without protection and working in the frontline were the main risk factors. A total of 88.8% HCW were vaccinated, all with a positive serological response in April 2021, but levels of antibodies decreased about 65%, and two vaccinated persons presented a negative serological test against spike protein in November 2021. Levels of spike antibodies were higher in those vaccinated with Moderna compared with Pfizer and the percentage of antibody reduction was higher with Pfizer vaccine. Conclusions: This study shows that seroprevalence of SARS-CoV-2 antibodies among HCW doubled that of the general population and that protection both at the workplace and in the socio-familial field was associated with a lower risk of infection, which stabilized after vaccination. (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Public Health Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu